Related Experiment Video
Updated: Aug 23, 2026
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients
Julia C Sansbury1, Barbara Cocuroccia, Joseph L Jorizzo
1Department of Dermatology and Pathology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. jjurgens@wfubmc.edu
Abstract:
Scleromyxedema is a generalized, papular, and sclerodermoid form of lichen myxedematosus associated with monoclonal gammopathy and systemic changes. Despite anecdotal reports of success with various agents, no satisfactory treatments are currently available. We report 3 adult patients with recalcitrant scleromyxedema associated with paraproteinemia who were treated with thalidomide. All 3 patients had marked improvement of the skin lesions and joint mobility after the first 2 months of therapy, with further amelioration after 4 months, and reduction in paraprotein levels.